Scientist or laboratory researcher in protective mask and laboratory gloves investigating sample. Medical diagnosis, research and science background.

uchar/iStock via Getty Images

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is expected to release results from its phase 1/2 study, using BBP-631 for the treatment of patients with congenital adrenal hyperplasia [CAH], in the early part of 2024. This is another catalyst for

Source link